Aurigene Discovery Technologies Limited To Present Its CDK7, Dual PD-1/VISTA And IRAK4 Inhibitor Programs At AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics (November 5-9, Boston, MA)
Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program, which is currently in Lead Optimization.
(Logo: http://photos.prnewswire.com/prnh/20130418/608115 )
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the AACR-NCI-EORTC International Conference.
Aurigene and Curis will present data on:
(A) First-in-class orally available PD-L1/VISTA antagonists for cancer therapy
(B) interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor
Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.
Poster Presentations
First-in-class orally available immune checkpoint antagonists: PD-L1/VISTA
Title: First-in-class orally available immune checkpoint antagonists for cancer therapy
Session ID: Poster Session A
Session Title: Immune Modulators
Session Date and Time: Friday Nov 6, 2015 12:15 PM - 3:15 PM
Location: Exhibit Hall C-D
Permanent Abstract Number: A96
Selective CDK7 Covalent Inhibitors
Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors Session Category: Experimental and Molecular Therapeutics
Session ID: Poster Session C
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date and Time: Sunday Nov 8, 2015 12:30 PM - 3:30 PM
Location: Exhibit Hall C-D
Permanent Abstract Number: C190
Novel, selective IRAK4 Inhibitors for Oncology
Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models
Session ID: Poster Session C
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date and Time: Sunday Nov 8, 2015 12:30 PM - 3:30 PM
Location: Exhibit Hall C-D
Permanent Abstract Number: C191
About Aurigene:
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene's website at http://aurigene.com/.
Media Contact:
Rajshree KT
Director Corporate Development & Strategy
+91-40-4465 7777
pr@aurigene.com
Help employers find you! Check out all the jobs and post your resume.